CSE: BUX | OTCQB: BMKDF | FSE: 20B
(Available Soon)
(Available Soon)
CSE: BUX | OTCQB: BMKDF | FSE: 20B
What drives us is simple: research that ends in a decision. We invest in science rigorous enough to publish and specific enough for a clinician to act on.
BioMark combines evidence-based metabolomic science with AI/ML to transform complex cancer-associated metabolic patterns into a clinically interpretable score and actionable report.
BioMark is an oncology-focused company developing advanced, near-to-market liquid biopsy diagnostic technologies. Our approach is designed to make cancer screening more comfortable for patients, support better outcomes, and enable earlier detection, when treatment is most effective.
BioMark holds a portfolio of intellectual property for the detection and quantitation of metabolites, forming the foundation of our diagnostic platform.
Our global team brings together hand-picked scientists, engineers, and medical professionals with proven track records. United by a shared goal, we are working to bring our innovative technology to market and to improve the predictive accuracy of early-stage cancer detection. In everything we do, we hold ourselves to the highest regulatory, clinical, and scientific standards.
Since our founding in 2007, our mission has remained unchanged: to develop and commercialize innovative technologies that improve the accuracy and prediction of early-stage cancer diagnosis.
Cancer care shouldn’t depend on where you live or which clinic you can reach. While we work closely with physicians and medical institutions, our goal reaches further: to empower individuals and nations with universal access to effective cancer diagnostic tools.
At BioMark, we are working to make effective cancer management solutions faster and more widely available, because earlier answers can mean better outcomes for patients everywhere.
Biomarkers are central to every stage of cancer care, from early detection and diagnosis to treatment monitoring and survivorship. That is why BioMark applies the highest levels of scientific and clinical rigor to every aspect of our development process.
Through meticulous analytical validation, robust clinical validation, and thorough assessment of clinical utility, we ensure our metabolite-based technologies meet the stringent requirements for safe, reliable integration into routine patient care.
This uncompromising commitment to excellence is embedded in BioMark’s daily operations and drives everything we do.
Founder, CEO, & Director
Chief Financial Officer
Chief Scientific Officer
Director
Director
Director
Strategic and Financial Advisor. Former President of Nasdaq
Innovation and Investment Strategy
AI and ML Strategic Advisor
Government Liaison and Community Engagement
Professor, Computing Science and Biological Sciences, University of Alberta
M.D., The Ohio State University, Director of the Division of Medical Oncology at OSUCCC-James
M.D., University Service Professor of Medicine, The Johns Hopkins Hospital
Professor, Pharmacology and Therapeutics, University of Manitoba
Assistant Professor of Data Science, Harrisburg University
MNP LLP
Accounting, Business Consulting, and Tax Services
Legal Counsel – Corporate: Cozen O’Connor
Legal Counsel – Patent: ROBIC LLP
Endeavor Trust Corporation
BioMark’s innovative metabolomics and AI platform is earning broad acclaim from top academic institutions, government bodies, and industry leaders, underscoring its promise to revolutionize early cancer detection.
NRC Horizon Europe Funding: Secured to support European expansion and collaborative research.
Raised a total of approximately CAD $4.26M–$4.5M through private placements (demonstrating investor support in a challenging market).
Manitoba Lung Association Grant: Support for a pilot First Nations lung cancer detection program (advancing health equity and community access).
Additional non-dilutive grant funding secured from NRC-IRAP, Mitacs, Research Manitoba, and City of Quebec, contributing to a total of over CAD $365,000 in grants during the fiscal year (as highlighted in company FY2025 achievements).
Research Manitoba IPoC Grant + Mitacs Accelerate: Over $290,000 in combined non-dilutive funding over a two-year period. Project: “Examination of lipid nanoparticle loaded hydrogels for localized silencing of spermidine/spermine acetyl transferase-1 (SAT1) expression in tumor and enhanced radiation and chemotherapy response” (animal proof-of-concept study). Led by Dr. Donald Miller, University of Manitoba. Focuses on improving treatment response in Glioblastoma and other cancers.
City of Quebec – Vision Entrepreneuriale Québec 2026: CAD $231,000 non-dilutive funding awarded to BioMark Diagnostic Solutions Inc. (wholly owned subsidiary) to accelerate commercialization and market development activities of its proprietary lung cancer detection assay. The funding supports business development in a clinically approved lab environment in Quebec.
NRC-IRAP: CAD $185,900 in non-dilutive funding and advisory services.
Global Affairs Canada (GAC) – CanExport Innovation Program: CAD $13,275.
Project: Development of a quantitative assay to measure drug metabolites for cancer treatment monitoring and relapse surveillance using BioMark’s metabolomic liquid biopsy platform.
University of Alberta / TMIC Spark Grant: C$150,000 awarded to collaborators at the Metabolomics Innovation Centre (TMIC) to evaluate and validate BioMark’s metabolite biomarker panel for early lung cancer detection (Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition).
Collaborative Health Research Projects (CHRP) Funding: Jointly supported by CIHR, NSERC, and SSHRC. BioMark served as the industrial partner on the grant.
Going Global Innovation (GGI) – Canadian Trade Commissioner Service: Funding to support travel to Japan and the United States to seek partners and establish collaborative R&D agreements.
BIAP (Business Innovation Access Program) under NRC-IRAP: Funding for “Novel Recombinant Antibodies to Assess SSAT-1 Activity as a Biomarker for the Diagnosis of Cancer” (led by Dr. Horacio Bach).
NRC-IRAP Funding: Support for developing prototypes for cancer screening kits and IR system.
Genome BC Funding: For “Raman Quantification of Cancer Biomarkers for Early Lung Cancer Detection” (in collaboration with Dr. Reuven Gordon and Dr. Fraser Hof, University of Victoria).
NSERC Engage Grants: Six grants in collaboration with professors from University of British Columbia, University of Victoria, University of Waterloo, University of Alberta, and University of Manitoba.
Mitacs: Five projects supported through the Mitacs program, with ongoing commitment to fund additional postdoctoral students.
CSB (Commercialization Support for Business): Funding under the Minister of Jobs and the Economy, Government of Manitoba.
BioMark is actively expanding its network of strategic collaborations with leading researchers, institutions, and organizations dedicated to transforming cancer diagnostics. If your work aligns with advancing metabolomics-based liquid biopsy technologies — whether through clinical sample access, analytical method development, or co-development partnerships — we would welcome the opportunity to connect. Please email [email protected] to explore how we can work together.
Thank you for your interest in BioMark Diagnostics. We are continuously driven by innovation and a shared passion for transforming healthcare through advanced diagnostics. While we do not have any open job listings at this time, we are always eager to connect with exceptionally talented individuals. If your expertise lies in Artificial Intelligence, Machine Learning, Healthcare Science, Cancer Research, or Metabolic Sciences, we invite you to share your resume and a brief introduction for future consideration. Please feel free to send your inquiries to our team via [email protected]
If you have been contacted by someone claiming to represent our company regarding a job opportunity, please exercise caution. Do not provide any personal, confidential, or financial information until you have verified the recruiter’s identity. To confirm whether a recruiter is genuinely affiliated with us, please contact us directly at [email protected].
If you believe you have been targeted by a fraudulent recruiter, we encourage you to report the incident to your local police department.
No openings at this time